Crinetics Pharmaceuticals operates in the drug sector, and on August 8, 2025, its stock underperformed the general market index. Investors used Zacks Rank to track earnings revisions.
2 reports, 2 independent
Updated Aug 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Crinetics Pharmaceuticals operates in the drug sector, and on August 8, 2025, its stock underperformed the general market index. Investors used Zacks Rank to track earnings revisions.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Crinetics Pharmaceuticals
company in San Diego, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksCrinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Esti
- Simply Wall St.Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans Just because a business does not make any money, does not mean that the stock will go down. For example, altho